vs
太平洋生物科学（ASMB）与景顺（IVR）财务数据对比。点击上方公司名可切换其他公司
景顺的季度营收约是太平洋生物科学的2.0倍（$21.3M vs $10.8M），景顺净利率更高（242.2% vs -85.2%，领先327.5%），太平洋生物科学同比增速更快（57.6% vs 55.4%）
该公司是一家成立于2004年的美国生物科技企业，主要研发生产基因测序相关设备，同时也开展新型实时生物观测技术相关业务。目前拥有两大核心测序平台，分别是基于零模波导特性的单分子实时测序平台，以及结合天然核苷酸无痕连接技术的结合测序平台。
景顺是一家美国独立投资管理公司，总部位于佐治亚州亚特兰大，在全球20个国家设有分支机构。景顺旗下拥有景顺、景顺 perpetual、PowerShares等多个品牌，其普通股纳入标普500指数，在纽约证券交易所挂牌交易。
ASMB vs IVR — 直观对比
营收规模更大
IVR
是对方的2.0倍
$10.8M
营收增速更快
ASMB
高出2.2%
55.4%
净利率更高
IVR
高出327.5%
-85.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.8M | $21.3M |
| 净利润 | $-9.2M | $51.5M |
| 毛利率 | — | — |
| 营业利润率 | -100.9% | — |
| 净利率 | -85.2% | 242.2% |
| 营收同比 | 57.6% | 55.4% |
| 净利润同比 | 4.3% | 1368.7% |
| 每股收益（稀释后） | $-0.72 | $0.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMBIVR
| Q4 25 | — | $21.3M | ||
| Q3 25 | $10.8M | $17.6M | ||
| Q2 25 | $9.6M | $17.7M | ||
| Q1 25 | $9.4M | $18.8M | ||
| Q4 24 | $7.4M | $13.7M | ||
| Q3 24 | $6.8M | $7.5M | ||
| Q2 24 | $8.5M | $8.6M | ||
| Q1 24 | $5.8M | $7.0M |
净利润ASMBIVR
| Q4 25 | — | $51.5M | ||
| Q3 25 | $-9.2M | $53.5M | ||
| Q2 25 | $-10.2M | $-23.3M | ||
| Q1 25 | $-8.8M | $19.6M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | $-9.6M | $40.7M | ||
| Q2 24 | $-11.2M | $-13.5M | ||
| Q1 24 | $-9.1M | $29.1M |
营业利润率ASMBIVR
| Q4 25 | — | — | ||
| Q3 25 | -100.9% | — | ||
| Q2 25 | -115.2% | — | ||
| Q1 25 | -105.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -160.1% | — | ||
| Q2 24 | -143.0% | — | ||
| Q1 24 | -185.5% | — |
净利率ASMBIVR
| Q4 25 | — | 242.2% | ||
| Q3 25 | -85.2% | 303.6% | ||
| Q2 25 | -105.9% | -131.6% | ||
| Q1 25 | -93.6% | 104.4% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | -140.4% | 542.2% | ||
| Q2 24 | -130.7% | -155.9% | ||
| Q1 24 | -156.9% | 415.9% |
每股收益（稀释后）ASMBIVR
| Q4 25 | — | $0.72 | ||
| Q3 25 | $-0.72 | $0.74 | ||
| Q2 25 | $-1.33 | $-0.40 | ||
| Q1 25 | $-1.17 | $0.26 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $-1.51 | $0.63 | ||
| Q2 24 | $-1.98 | $-0.38 | ||
| Q1 24 | $-1.66 | $0.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.5M | $56.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $182.7M | $797.5M |
| 总资产 | $240.0M | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASMBIVR
| Q4 25 | — | $56.0M | ||
| Q3 25 | $22.5M | $58.5M | ||
| Q2 25 | $24.0M | $59.4M | ||
| Q1 25 | $23.4M | $42.9M | ||
| Q4 24 | $38.3M | $73.4M | ||
| Q3 24 | $28.5M | $48.3M | ||
| Q2 24 | $19.2M | $58.8M | ||
| Q1 24 | $18.7M | $59.9M |
股东权益ASMBIVR
| Q4 25 | — | $797.5M | ||
| Q3 25 | $182.7M | $769.6M | ||
| Q2 25 | $18.1M | $709.4M | ||
| Q1 25 | $27.1M | $759.2M | ||
| Q4 24 | $33.4M | $730.7M | ||
| Q3 24 | $26.0M | $857.0M | ||
| Q2 24 | $34.7M | $759.2M | ||
| Q1 24 | $32.6M | $785.6M |
总资产ASMBIVR
| Q4 25 | — | $6.5B | ||
| Q3 25 | $240.0M | $6.0B | ||
| Q2 25 | $80.8M | $5.4B | ||
| Q1 25 | $99.0M | $6.2B | ||
| Q4 24 | $119.2M | $5.7B | ||
| Q3 24 | $100.3M | $6.1B | ||
| Q2 24 | $115.3M | $5.1B | ||
| Q1 24 | $119.9M | $5.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.1M | $157.1M |
| 自由现金流经营现金流 - 资本支出 | $-15.2M | — |
| 自由现金流率自由现金流/营收 | -140.7% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | — | 3.05× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASMBIVR
| Q4 25 | — | $157.1M | ||
| Q3 25 | $-15.1M | $37.3M | ||
| Q2 25 | $-16.8M | $40.6M | ||
| Q1 25 | $-23.4M | $19.3M | ||
| Q4 24 | $-51.1M | $183.2M | ||
| Q3 24 | $-15.2M | $30.8M | ||
| Q2 24 | $-17.1M | $33.0M | ||
| Q1 24 | $-18.4M | $57.5M |
自由现金流ASMBIVR
| Q4 25 | — | — | ||
| Q3 25 | $-15.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-51.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-17.1M | — | ||
| Q1 24 | $-18.4M | — |
自由现金流率ASMBIVR
| Q4 25 | — | — | ||
| Q3 25 | -140.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -695.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -200.6% | — | ||
| Q1 24 | -317.7% | — |
资本支出强度ASMBIVR
| Q4 25 | — | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.2% | — |
现金转化率ASMBIVR
| Q4 25 | — | 3.05× | ||
| Q3 25 | — | 0.70× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.98× | ||
| Q4 24 | — | 52.24× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
